crisp_bio

論文・記事紹介：CRISPR生物学・技術開発・応用 (ゲノム工学, エピゲノム工学, 代謝工学/遺伝子治療, 分子診断/進化, がん, 免疫, 老化, 育種 - 結果的に生物が関わる全分野)； タンパク質工学；情報資源・生物資源；新型コロナウイルスの起源・ワクチン・後遺症；研究公正

｜CRISPR

[注] プロシーディング [Cancer Res (2024) 84 (6_Supplement)] から抽出し、スタイトルとアブストラクトへのリンクのみを記載。必ずしも網羅的リストにはなっておりません。
  1. CRISPR/saCas9 and CRISPR/spCas9 systems for combinatorial genetic screens (CRISPR-KO, CRISPRa, CRISPRi) https://doi.org/10.1158/1538-7445.AM2024-2950
  2. CRISPR-cas9 genetic targeting of metastatic pancreatic cancer. https://doi.org/10.1158/1538-7445.AM2024-7243
  3. Identifying mechanisms of acquired resistance to lorlatinib utilizing a genome-wide CRISPR-Cas9 screen. https://doi.org/10.1158/1538-7445.AM2024-3357
  4. CRISPR in vivo screen utilizing removable Cas9 system to identify epigenetic immune response modulators in antigen-sensitive mouse syngeneic models. https://doi.org/10.1158/1538-7445.AM2024-2634
  5. In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables ATAD3A gene depletion to enhance RAS-targeted therapy. https://doi.org/10.1158/1538-7445.AM2024-1219
  6. Metabolic CRISPR-Cas9 screening identifies loss of mitochondriaGene Min triple-negative breast cancer to promote lung metastasis via immune modulation. https://doi.org/10.1158/1538-7445.AM2024-1397
  7. Advancing therapeutic interventions for NUT carcinoma: Orchestrating the precision of CRISPR/Cas9-mediated NUTM1 suppression and synergistic ADC strategies. https://doi.org/10.1158/1538-7445.AM2024-1910
  8. Harnessing in vivo CRISPR screen to uncover metabolic dependencies during cancer progression.https://doi.org/10.1158/1538-7445.AM2024-2939
  9. Improving CAR T cell efficacy in pancreatic cancer using an in vivo CRISPR Cas9 screen.https://doi.org/10.1158/1538-7445.AM2024-34
  10. A genome wide CRISPR-Cas9 screen identifies mediators of resistance to dual PI3K/mTOR inhibition in glioblastoma multiforme. https://doi.org/10.1158/1538-7445.AM2024-5841
  11. KLIPP: Precision targeting of cancer with CRISPR. https://doi.org/10.1158/1538-7445.AM2024-6569
  12. CRISPR/Cas9 screening identifies genes affecting the sensitivity to the copanlisib/venetoclax combination in lymphoma cells. https://doi.org/10.1158/1538-7445.AM2024-5836
  13. Technical feasibility of CRISPR-based functional profiling for solid tumor precision medicine.https://doi.org/10.1158/1538-7445.AM2024-2500
  14. Generating primary mouse models of diffuse midline glioma through a combination of the RCAS/tv-a retrovirus system and CRISPR/Cas9 gene editing. https://doi.org/10.1158/1538-7445.AM2024-1437
  15. Genome wide CRISPR/Cas9 library screening identifies aurora kinase A as a regulator of elraglusib sensitivity in pancreatic cancer. https://doi.org/10.1158/1538-7445.AM2024-4658
  16. In vivo CRISPR/Cas9 transcriptional activation screen leads to discovery of INAFM2, a novel driver of metastasis. https://doi.org/10.1158/1538-7445.AM2024-1560
  17. A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeutics. https://doi.org/10.1158/1538-7445.AM2024-5124
このエントリーをはてなブックマークに追加

コメント

コメントフォーム
評価する
  • 1
  • 2
  • 3
  • 4
  • 5
  • リセット
  • 1
  • 2
  • 3
  • 4
  • 5
  • リセット
顔
星